Champions Oncology, Inc. (CSBR) P/E Ratio History
Deep ValueTrading at 20.1x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2008–2026
Loading P/E history...
P/E Ratio Analysis
As of June 28, 2026, Champions Oncology, Inc. (CSBR) trades at a price-to-earnings ratio of 20.1x, with a stock price of $6.63 and trailing twelve-month earnings per share of $-0.16.
The current P/E is 94% below its 5-year average of 361.4x. Over the past five years, CSBR's P/E has ranged from a low of 22.0x to a high of 1577.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.0x, CSBR is roughly in line with its sector peers. The sector includes 231 companies with P/E ratios ranging from 0.0x to 191.4x.
Relative to the broader market, CSBR trades at a notable discount to the S&P 500 median P/E of 25.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our CSBR DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
CSBR Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
CSBR P/E vs Peers
Biopharma Services and CROs peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $191M | 3.9Lowest | 3.80 | +49%Best | |
| $44B | 42.2 | 2.95 | +23% | |
| $32B | 24.4 | 0.60Best | +5% | |
| $15B | 34.5 | 1.08 | +21% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
CSBR Historical P/E Data (2008–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | Oct 31 2025 | $6.84 | $0.17 | 41.0x | -89% |
| FY2026 Q1 | - | $6.32 | $0.20 | 31.6x | -91% |
| FY2025 Q4 | Apr 30 2025 | $7.15 | $0.33 | 22.0x | -94% |
| FY2025 Q3 | Jan 31 2025 | $10.99 | $0.45 | 24.6x | -93% |
| FY2023 Q2 | Oct 31 2022 | $6.94 | $0.00 | 1577.3x | +336% |
| FY2023 Q1 | Jul 31 2022 | $8.66 | $0.02 | 352.0x | -3% |
| FY2022 Q4 | Apr 30 2022 | $7.68 | $0.04 | 216.9x | -40% |
| FY2022 Q3 | Jan 31 2022 | $8.02 | $0.03 | 320.8x | -11% |
| FY2022 Q2 | Oct 31 2021 | $9.77 | $0.04 | 268.4x | -26% |
| FY2022 Q1 | Jul 31 2021 | $10.45 | $0.02 | 597.1x | +65% |
| FY2021 Q4 | Apr 30 2021 | $10.73 | $0.04 | 301.4x | -17% |
| FY2019 Q4 | - | $9.08 | $0.01 | 687.9x | +90% |
| FY2008 Q4 | Apr 30 2008 | $15.36 | $0.03 | 546.6x | +51% |
| FY2008 Q3 | - | $10.92 | $0.15 | 72.4x | -80% |
Average P/E for displayed period: 361.4x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
18+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
CSBR — Frequently Asked Questions
Quick answers to the most common questions about buying CSBR stock.
What is CSBR's P/E ratio?
Champions Oncology, Inc. (CSBR) trailing twelve-month P/E ratio is 20.1x, based on TTM diluted EPS of $-0.16. The 5-year average P/E is 361.4x and the historical range spans 22.0x to 1577.3x.
Is CSBR stock overvalued or undervalued?
CSBR trades at 20.1x P/E, below its 5-year average of 361.4x. At the 0th percentile of its historical range (22.0x–1577.3x), the stock is priced at a discount to its own history.
Is CSBR stock expensive?
No, CSBR is not expensive on a historical basis. The current P/E of 20.1x is below the 5-year average of 361.4x and sits at the 0th percentile of its valuation range.
What is CSBR's historical P/E range?
Over the past 5 years, CSBR's P/E ratio has ranged from 22.0x to 1577.3x, with a median of 301.4x and an average of 361.4x. The current P/E of 20.1x places the stock at the 0th percentile of this range. Full historical data spans 2008–2026.
How does CSBR's P/E compare to the S&P 500?
CSBR trades at 20.1x P/E versus the S&P 500 median of 25.3x. The 21% discount to the market suggests lower growth expectations or perceived higher risk.
How does CSBR's valuation compare to Healthcare peers?
Champions Oncology, Inc. P/E of 20.1x compares to the Healthcare sector median of 23.0x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is CSBR's PEG ratio?
CSBR PEG ratio is N/A, based on a P/E of 20.1x and EPS growth of 161.1%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is CSBR's earnings yield?
CSBR earnings yield is 4.98%, the inverse of its 20.1x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.